May 9 (Reuters) - LONZA GROUP AG :: *STRONG CDMO^1 PERFORMANCE IN Q1 2025, IN LINE WITH EXPECTATIONS FOR FY 2025 *CDMO OUTLOOK 2025 CONFIRMED WITH CER^2 SALES GROWTH APPROACHING 20% AND CORE EBITDA MARGIN APPROACHING 30% *CHI CONFIRMS ITS OUTLOOK TO RETURN TO LOW-TO-MID-SINGLE-DIGIT CER SALES GROWTH IN 2025 WITH AN IMPROVING CORE EBITDA MARGIN IN MID-TWENTIES *MID-TERM OUTLOOK CONFIRMED *Q1 2025, LONZA EXPERIENCED A HEALTHY LEVEL OF CONTRACT SIGNINGS ACROSS WHOLE CDMO BUSINESS *DOES NOT ANTICIPATE A MATERIAL FINANCIAL IMPACT FROM POTENTIAL TARIFFS *LONZA NOW ANTICIPATES START OF OPERATIONS AT ITS NEW COMMERCIAL-SCALE ASEPTIC DRUG PRODUCT FACILITY IN STEIN (CH) IN 2027 *IN Q1 2025, LONZA EXPERIENCED A HEALTHY LEVEL OF CONTRACT SIGNINGS ACROSS WHOLE CDMO BUSINESS *CUSTOMER INTEREST IN VACAVILLE IS STRONG, WITH A THIRD LONG-TERM CUSTOMER CONTRACT SECURED AND A NUMBER OF CONTRACT NEGOTIATIONS ONGOING *MAKING GOOD PROGRESS WITH PREPARATIONS FOR EXIT OF CHI BUSINESS *CHI BUSINESS: CURRENTLY PLANNING NECESSARY CARVE-OUT MEASURES
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.